TriArm Therapeutics

Cell therapy company focused on innovative autologous non-viral manufacturing solutions that result in very low cost and fast vein to vein delivery. TriArm’s novel technology platforms enable generation of a higher proportion of immune-naïve, potent, and persistent T cells, increasing yield while also avoiding cytokine storm